Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Number of Patients' Rheumatologists Using SLE@Duke |
Collected from EMR (electronic medical record). This is a composite measure that includes documentation in the clinic note of any component of SLE@Duke: (1) Type 1 & 2 SLE Model mentioned, (2) dotphrase used, (3) Type 1 & Type 2 PGAs (Physician Global Assessments) scored in note, (4) handout mentioned, (5) Type 2 symptoms discussed, or (6) purple sheet documented. |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Length of Clinic Visits |
Collected from EMR (electronic medical record). |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Change in Physician Satisfaction With Visits With Lupus Patients, as Measured by Provider Survey |
Satisfaction was measured on a scale of 1-5, where 1 = never and 5 = always in response to the statement: "After seeing a patient with lupus, I leave the exam room feeling satisfied with the encounter." |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Number of Lupus Patients With Assessment of Type 1 and 2 SLE in Note |
Collected from EMR (electronic medical record). |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Number of Lupus Patients With Type 2 SLE Treatment in Note |
Collected from EMR (electronic medical record). |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Perceived Benefits of SLE@Duke, as Measured by Provider Interviews |
In-depth interviews with participating rheumatologists related to the intervention, including acceptability, utility, implementation, integration and practicality of SLE@Duke. |
4 weeks |
|
Primary |
Perceived Barriers of SLE@Duke, as Measured by Provider Interviews |
In-depth interviews with participating rheumatologists related to the intervention, including acceptability, utility, implementation, integration and practicality of SLE@Duke. |
4 weeks |
|
Primary |
How SLE@Duke Fit Into Work Flow, as Measured by Provider Interviews |
In-depth interviews with participating rheumatologists related to the intervention, including acceptability, utility, implementation, integration and practicality of SLE@Duke. |
4 weeks |
|
Primary |
Number of Lupus Patients With PRO (Patient-reported Outcomes) in Note |
Collected from EMR (electronic medical record). |
Intervention period (month 2), month 5 |
|
Primary |
Difference in Perceived Quality of Visit, as Measured by Patient Survey |
Each question pertaining to quality of visit was measured on a scale of 1-5, where 1 = strongly disagree and 5 = strongly agree. Different patients completed the survey at month 1 and month 2. The scores at month 1 were averaged, then subtracted from the average score at month 2. |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Discussion of the Type 1 and 2 Model, as Measured by Patient Survey |
The patient survey asked patients to respond "Yes" or "No" in response to the statement: "My rheumatologist discussed Type 1 & Type 2 lupus with me today." |
Intervention period (month 2) |
|
Primary |
Difference in Understanding of Lupus Activity & Treatment Plan, as Measured by Patient Survey |
Questions pertaining to understanding were measured on a scale of 1-5, where 1 = strongly disagree and 5 = strongly agree. Different patients completed the survey at month 1 and month 2. The scores at month 1 were averaged, then subtracted from the average score at month 2. |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Change in Discussion of the Type 1 and 2 Model, as Measured by Provider Survey |
Discussion of the Type 1 & 2 SLE Model was measured on a scale of 1-5, where 1 = "never" and 5 = "always" in response to the statement: "I discuss the Type 1 & 2 SLE Model with the patient." |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Change in Acceptability of SLE@Duke, as Measured by Provider Survey |
Questions pertaining to acceptability of SLE@Duke were measured on a scale of 1-5, where 1 = completely disagree and 5 = completely agree. |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Change in Appropriateness of SLE@Duke, as Measured by Provider Survey |
Questions pertaining to the appropriateness of SLE@Duke were measured on a scale of 1-5, where 1 = completely disagree and 5 = completely agree. |
Baseline (month 1), intervention period (month 2) |
|
Primary |
Change in Feasibility of SLE@Duke, as Measured by Provider Survey |
Questions concerning feasibility of SLE@Duke were measured on a scale of 1-5, where 1 = completely disagree and 5 = completely agree. |
Baseline (month 1), intervention period (month 2) |
|